Levofolinic Acid Medac

Levoleucovorin Disodium, the active ingredient in Levofolinic Acid Medac, is a folate analog presented as a solution for injection for intravenous use. It serves as an antineoplastic adjunct to rescue normal cells from the toxic effects of antifolate chemotherapy and to treat folate deficiency.

GNH USA supplies Levofolinic Acid Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Levofolinic Acid Medac is used as a folate rescue agent in oncology and metabolic care. - Rescue therapy after high‑dose methotrexate: reduces methotrexate‑induced toxicity and speeds recovery of normal cells. - Reduction of toxicity from antifolate chemotherapy: mitigates side effects of agents such as pemetrexed and other folate antagonists. - Treatment of folate deficiency: restores adequate folate levels in patients with documented deficiency.

Levofolinic Acid Medac may be associated with a range of adverse reactions.

Common Side Effects: - Nausea - Vomiting - Mild rash or erythema - Flushing - Fever - Headache

Serious or Rare Side Effects: - Anaphylactic reaction - Severe hypotension - Acute renal failure - Pulmonary edema - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Thrombocytopenia or severe bleeding disorders

Prior to administration, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal function: assess baseline creatinine and adjust use in renal impairment. - Hepatic function: monitor liver enzymes, especially in patients with existing liver disease. - Pregnancy: avoid unless the potential benefit justifies the risk to the fetus. - Known hypersensitivity: do not administer to patients with documented allergy to folate compounds. - Concomitant methotrexate timing: ensure appropriate interval to maximise rescue effect. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levofolinic Acid Medac can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Methotrexate: concurrent use may diminish rescue efficacy if timing is inappropriate. - Other antifolates (e.g., pemetrexed): may interfere with intended therapeutic effect.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect renal clearance of folate compounds. - Aminoglycoside antibiotics: potential additive nephrotoxicity. - Loop diuretics: may increase folate excretion and alter plasma levels.